Published in Am J Hum Genet on April 01, 1995
Dichotomous splicing signals in exon flanks. Genome Res (2005) 1.42
Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci (2014) 1.06
Is genotype determination useful in predicting the clinical phenotype in lysosomal storage diseases? J Inherit Metab Dis (2001) 0.92
Molecular diagnosis of German patients with late-onset glycogen storage disease type II. J Inherit Metab Dis (2008) 0.89
Seven cases of Pompe disease from Greece. J Inherit Metab Dis (2006) 0.82
Mutational analysis of the RB1 gene in Moroccan patients with retinoblastoma. Mol Vis (2011) 0.82
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature. J Neurol (2013) 0.80
Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents. Nucleic Acids Res (2013) 0.79
Identification and Functional Characterization of GAA Mutations in Colombian Patients Affected by Pompe Disease. JIMD Rep (2012) 0.78
Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T). J Inherit Metab Dis (2011) 0.78
From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides. Mol Ther Nucleic Acids (2016) 0.78
Familial adult-onset Pompe disease associated with unusual clinical and histological features. Acta Myol (2013) 0.77
GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells. Mol Ther Nucleic Acids (2017) 0.76
Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease. Mol Ther Nucleic Acids (2017) 0.76
Clinical Laboratory Experience of Blood CRIM Testing in Infantile Pompe Disease. Mol Genet Metab Rep (2015) 0.75
Genetic screening in Iranian patients with retinoblastoma. Eye (Lond) (2016) 0.75
Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience. Case Rep Neurol Med (2014) 0.75
A review of treatment of Pompe disease in infants. Biologics (2007) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci U S A (1972) 83.88
A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res (1976) 24.00
Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci U S A (1989) 13.66
Human growth hormone as a reporter gene in regulation studies employing transient gene expression. Mol Cell Biol (1986) 7.11
Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis. Nucleic Acids Res (1985) 6.52
alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease). Biochem J (1963) 3.95
Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients. Proc Natl Acad Sci U S A (1986) 3.49
Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex. EMBO J (1988) 2.44
Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain (1970) 1.72
The spectrum and diagnosis of acid maltase deficiency. Neurology (1973) 1.71
Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet (1994) 1.49
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest (1987) 1.45
Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II. J Biol Chem (1985) 1.43
The fine structure of the normal, neonatal mouse liver. Lab Invest (1965) 1.36
A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). Hum Mol Genet (1994) 1.35
Adult-onset acid maltase deficiency: a postmortem study. Muscle Nerve (1979) 1.33
Autophagic glycogenosis of late onset with mitochondrial abnormalities: light and electron microscopic observations. Mayo Clin Proc (1968) 1.33
Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem (1993) 1.32
Residual acid maltase activity in late-onset acid maltase deficiency. Neurology (1977) 1.31
Rodent and human acid -glucosidase. Purification, properties and inhibition by antibodies. Investigation in type II glycogenosis. Eur J Biochem (1972) 1.30
Characterization of the human lysosomal alpha-glucosidase gene. Biochem J (1990) 1.26
Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J (1990) 1.24
Simultaneous absence of alpha-1,4-glucosidase and alpha-1,6-glucosidase activities (pH 4) in tissues of children with type II glycogen storage disease. Biochemistry (1970) 1.22
Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet (1978) 1.20
Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun (1994) 1.17
Studies of lysosomal alpha-glucosidase. II. Kinetics of action of the rat liver enzyme. Biochemistry (1970) 1.15
Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem (1991) 1.15
Adult myopathy from glycogen storage disease due to acid maltase deficiency. Brain (1968) 1.13
Acid maltase deficiency in adults presenting as respiratory failure. Am J Med (1978) 1.11
Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites. Biochem J (1993) 1.05
Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele. Am J Hum Genet (1991) 0.99
Biosynthesis of acid alpha-glucosidase in late-onset forms of glycogenosis type II (Pompe's disease). FEBS Lett (1982) 0.98
A method for rapid prenatal diagnosis of glycogenosis II (Pompe's disease). Clin Chim Acta (1973) 0.96
[Muscular glycogenosis caused by alpha-1,4-glucosidase deficiency simulating progressive muscular dystrophy. (Clinical and enzyme study. Optic and electron microscopy)]. Arch Fr Pediatr (1965) 0.94
Acid alpha-glucosidase: kinetic and immunologic properties of enzyme variants in health and disease. Isozymes Curr Top Biol Med Res (1983) 0.92
Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA. Am J Hum Genet (1990) 0.91
The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J (1993) 0.90
Two mutations affecting the transport and maturation of lysosomal alpha-glucosidase in an adult case of glycogen storage disease type II. Hum Mutat (1993) 0.87
Hints for direct sequencing of PCR-generated single-stranded DNA. Biotechniques (1994) 0.85
Identification of a point mutation in the human lysosomal alpha-glucosidase gene causing infantile glycogenosis type II. Biochem Biophys Res Commun (1991) 0.84
Demonstration of acid alpha-glucosidase in different types of Pompe disease by use of an immunochemical method. J Neurol Sci (1985) 0.83
Multiple neutral maltase activities in normal and acid maltase-deficient human muscle. Exp Neurol (1984) 0.82
Identification of the base-pair substitution responsible for a human acid alpha glucosidase allele with lower "affinity" for glycogen (GAA 2) and transient gene expression in deficient cells. Am J Hum Genet (1990) 0.80
Identification of a missense mutation in an adult-onset patient with glycogenosis type II expressing only one allele. DNA Cell Biol (1991) 0.80
Developmental profile of striatal preprotachykinin gene expression. J Neurochem (1990) 0.80
Age-related changes in the proportion of amyloid precursor protein mRNAs in Alzheimer's disease and other neurological disorders. Brain Res Mol Brain Res (1992) 0.79
Age-related change in the proportion of amyloid precursor protein mRNAs in the gray matter of cerebral cortex. Neurosci Lett (1993) 0.78
Acid maltase deficiency: comparison of infantile, childhood, and adult types. Neurology (1970) 0.78
Separation of acid and neutral alpha-glucosidase isoenzymes from fetal and adult tissues, cultivated fibroblasts and amniotic fluid cells by DEAE-cellulose and sephadex G-100 column chromatography. Clin Chim Acta (1978) 0.77
Properties of the alpha-glucosidase from various human tissues in relation to glycogenosis type II (Pompe's disease). Clin Chim Acta (1977) 0.77
Immunocytochemical analysis of normal and acid maltase-deficient muscle cultures. Arch Neurol (1985) 0.76
The diagnosis of twin zygosity. Acta Genet Stat Med (1966) 5.06
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) (1991) 4.01
Assignment of direct and facilitated hemolytic plaques in mice to specific immunoglobulin classes. J Immunol (1968) 3.81
Weekend orthodontists. Br Dent J (1995) 2.58
Fractionation of splenic antibody-forming cells on glass bead columns. J Immunol (1967) 2.41
Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. J Natl Cancer Inst (1994) 2.24
Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med (1992) 2.18
Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab (2003) 2.17
Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A (2000) 2.13
Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med (1974) 2.04
Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med (1995) 1.99
Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med (1978) 1.96
Polyarthritis in rats following the systemic injection of Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum (1983) 1.75
Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet (1998) 1.75
Antibody to signal recognition particle in polymyositis. Arthritis Rheum (1990) 1.74
Autoantibodies are anti-idiotype antibodies to antiviral antibodies. Lancet (1983) 1.67
Studies of reticuloendothelial function in the mouse with model immune complexes. I. Serum clearance and tissue uptake in normal C3H mice. J Immunol (1979) 1.61
Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers. Arthritis Rheum (1976) 1.61
NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med (1979) 1.59
Severe, acute pulmonary disease in patients with systemic lupus erythematosus: ten years of experience at the National Institutes of Health. Semin Arthritis Rheum (1984) 1.58
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum (1997) 1.55
Lactobacillus casei cell wall-induced arthritis in rats: cell wall fragment distribution and persistence in chronic arthritis-susceptible LEW/N and -resistant F344/N rats. Arthritis Rheum (1984) 1.55
Modulation of AUUUA response element binding by heterogeneous nuclear ribonucleoprotein A1 in human T lymphocytes. The roles of cytoplasmic location, transcription, and phosphorylation. J Biol Chem (1997) 1.50
Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A (1999) 1.46
Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet (2001) 1.42
Lymphapheresis in rheumatoid arthritis. A randomized trial. Arthritis Rheum (1981) 1.41
Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med (1989) 1.40
Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med (1993) 1.38
Aspirin-induced depression of renal function. N Engl J Med (1977) 1.33
Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med (1978) 1.33
A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythematosus. Arthritis Rheum (1982) 1.31
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol (2001) 1.29
The role of autoantibodies in autoimmune disease. Annu Rev Immunol (1993) 1.28
Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) (2008) 1.26
Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum (1997) 1.21
The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect (1999) 1.20
Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis Rheum (1998) 1.20
hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo. Biochem Biophys Res Commun (1999) 1.19
The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) (2007) 1.18
A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol (1998) 1.17
Studies of reticuloendothelial function in the mouse with model immune complexes. II. Serum clearance, tissue uptake, and reticuloendothelial saturation in NZB/W mice. J Immunol (1979) 1.17
Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet (1992) 1.17
Role of autophagy in the pathogenesis of Pompe disease. Acta Myol (2007) 1.16
NIH conference. Systemic lupus erythematosus: insights from animal models. Ann Intern Med (1984) 1.16
The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A (1990) 1.15
Health-care workers positive for hepatitis B surface antigen. Are their contacts at risk? N Engl J Med (1975) 1.15
Influence of antigen on immune complex behavior in mice. J Clin Invest (1981) 1.14
The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum (2001) 1.14
The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization. J Exp Med (1988) 1.13
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab (2008) 1.13
Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest (1993) 1.12
Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med (1984) 1.11
Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol (1997) 1.10
Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest (1990) 1.10
Mouse macroglobulin antibody to sheep erythrocytes: a non-complement-fixing type. J Immunol (1968) 1.08
An abnormality of immune complex kinetics in murine lupus. J Immunol (1981) 1.08
Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther (2009) 1.06
Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol (1999) 1.05
Marrow granulocyte reserves in the rheumatic diseases. Arthritis Rheum (1973) 1.04
Systemic lupus erythematosus. Contrasts and comparisons. Ann Intern Med (1975) 1.03
Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence. J Struct Biol (2008) 1.02
The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians (1997) 1.02
NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med (1995) 1.02
Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol (1990) 1.01
A novel gene oriented in a head-to-head configuration with the human histidyl-tRNA synthetase (HRS) gene encodes an mRNA that predicts a polypeptide homologous to HRS. Biochem Biophys Res Commun (1995) 1.01
The specificity of uptake of model immune complexes and other protein aggregates by the murine reticuloendothelial system. J Immunol (1980) 1.01
Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am (1997) 1.01
Stable model immune complexes produced by bivalent affinity labeling haptens: in-vivo survival. Mol Immunol (1979) 1.00
Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum (1992) 1.00
Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum (1991) 0.98
Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet (2001) 0.98
Molecular detection of persistent Borrelia burgdorferi in a man with dermatomyositis. Clin Exp Rheumatol (1992) 0.98
Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol (2000) 0.98
Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum (1998) 0.97
Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency. Am J Hum Genet (1994) 0.97
Treatment of chronic active hepatitis. An analysis of three controlled trials. Gastroenterology (1977) 0.97
Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol (2000) 0.96
Functional expression of human mutant phosphofructokinase in yeast: genetic defects in French Canadian and Swiss patients with phosphofructokinase deficiency. Am J Hum Genet (1995) 0.96
Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 0.95
A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum Mol Genet (1996) 0.95
Epitopes of the p70 and p80 (Ku) lupus autoantigens. J Immunol (1991) 0.95
Removing substances from blood by affinity chromatography. II. Removing bilirubin from the blood of jaundiced rats by hemoperfusion over albumin-conjugated agarose beads. J Clin Invest (1974) 0.95
Monocyte receptors for the Fc portion of IgG are increased in systemic lupus erythematosus. J Immunol (1984) 0.95